Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 8.87% is 108% above its 5-year average of -114.36%, near the high end of its 5-year range (-1170.32%–8.87%).
As of the fiscal period ended Tuesday, June 30, 2026. 184.67% above its 12-month average of 3.11%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
8.87%
EBITDA MARGIN AVG TTM
3.11%
EBITDA MARGIN AVG 3Y
0.62%
EBITDA MARGIN AVG 5Y
-0.40%
EBITDA MARGIN AVG 10Y
-7.52%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+184.67%
CURRENT VS 3Y AVG
+1339.68%
CURRENT VS 5Y AVG
+2301.77%
CURRENT VS 10Y AVG
+217.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Teladoc Health, Inc.
Market Cap
$1.30B
EBITDA Margin
8.87%
TTM Avg
3.11%
3Y Avg
0.62%
5Y Avg
-0.40%
Market Cap
$427.00M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$2.43B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$15.31M
EBITDA Margin
-114.42%
TTM Avg
-123.66%
3Y Avg
-106.79%
5Y Avg
-92.91%
Market Cap
$2.90B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$7.05B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$7.23B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$9.12B
EBITDA Margin
-11.84%
TTM Avg
-53.07%
3Y Avg
-52.51%
5Y Avg
-64.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Teladoc Health, Inc. (TDOC) | $1.30B | 8.87% | 3.11% | 0.62% | -0.40% |
| NRC Health (NRC)vs › | $458.40M | 21.99% | 25.40% | 28.98% | 31.97% |
| Shoulder Innovations, Inc. (SI)vs › | $427.00M | -48.80% | -44.09% | -45.35% | -45.35% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.43B | 16.41% | 1.22% | -1.65% | 4.31% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -114.42% | -123.66% | -106.79% | -92.91% |
| TransMedics Group, Inc. (TMDX)vs › | $2.90B | 22.42% | 17.70% | -0.76% | -37.34% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.05B | 6.82% | 6.08% | -0.44% | -8.67% |
| Oscar Health, Inc. (OSCR)vs › | $7.23B | -3.14% | -1.08% | -5.02% | -19.32% |
| Tempus AI, Inc. (TEM)vs › | $9.12B | -11.84% | -53.07% | -52.51% | -64.32% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.49B | 18.42% | 17.41% | 19.12% | 20.05% |
Gross Margin
73.5%
EBITDA Margin
8.9%
Operating Margin
-7.0%
Net Margin
-7.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 8.87% |
| 2026-03-31 | 7.41% |
| 2025-12-31 | 6.82% |
| 2025-09-30 | -6.62% |
| 2025-06-30 | -0.90% |
| 2025-03-31 | -11.86% |
| 2024-12-31 | 0.89% |
| 2024-09-30 | 1.46% |
| 2024-06-30 | -120.69% |
| 2024-03-31 | -3.11% |
| 2023-12-31 | 5.83% |
| 2023-09-30 | 1.05% |
| 2023-06-30 | -2.44% |
| 2023-03-31 | -3.80% |
| 2022-12-31 | -589.94% |
| 2022-09-30 | -3.03% |
| 2022-06-30 | -513.77% |
| 2022-03-31 | -1170.32% |
| 2021-12-31 | -0.59% |
| 2021-09-30 | -1.50% |
| 2021-06-30 | -5.32% |
| 2021-03-31 | -7.76% |
| 2020-12-31 | -109.75% |
| 2020-09-30 | -2.06% |
| 2020-06-30 | 1.13% |
| 2020-03-31 | -6.25% |
| 2019-12-31 | -6.71% |
| 2019-09-30 | -6.18% |
| 2019-06-30 | -8.55% |
| 2019-03-31 | -8.81% |
| 2018-12-31 | -6.75% |
| 2018-09-30 | -5.44% |
| 2018-06-30 | -10.68% |
| 2018-03-31 | -12.09% |
| 2017-12-31 | -22.24% |
| 2017-09-30 | -22.03% |
| 2017-06-30 | -26.52% |
| 2017-03-31 | -28.43% |
| 2016-12-31 | -28.43% |
| 2016-09-30 | -54.51% |
| 2016-06-30 | -48.72% |
| 2016-03-31 | -49.12% |
| 2015-12-31 | -56.54% |
| 2015-09-30 | -55.60% |
| 2015-06-30 | -83.84% |
| 2015-03-31 | -70.90% |
| 2014-12-31 | -42.89% |
| 2014-09-30 | -29.41% |
| 2014-06-30 | -22.39% |
| 2014-03-31 | -18.86% |
